Figure 4: Inhibitory effects of ⁴⁰Gap27 on platelet function are not solely due to defects in granule secretion or TXA₂ synthesis.

The level of fibrinogen binding was measured in the presence and absence of apyrase (4 U ml⁻¹) or indomethacin (20 μM), or both (at the same concentration) on 0.5 (a) and 1 μg ml⁻¹ (b) CRP-XL activation in human PRP. The level of fibrinogen binding obtained in the absence of apyrase or indomethacin was taken as 100%. Similarly, 0.5 (c) and 1 μg ml⁻¹ (d) CRP-XL-induced fibrinogen binding was measured in the presence or absence of ⁴⁰Gap27 (100 μg ml⁻¹) in addition to apyrase (4 U ml⁻¹) and/or indomethacin (20 μM). The level of fibrinogen binding obtained in the absence of ⁴⁰Gap27 (but in the presence of apyrase and/or indomethacin) was taken as 100% to compare the inhibitory levels obtained with ⁴⁰Gap27. Data represent mean±s.d. (n=3; Student’s t-test, *P<0.05 and **P<0.01). A, apyrase; C, control; G, ⁴⁰Gap27; I, indomethacin.